EndoCAb and LBP: a heads-up warning for microvascular complications in Type-I diabetes?
Thursday, June 23, 2016
Short summary of Vivekanandhan Aravindhan et al; Chronic Endotoxemia in Subjects with Type-1 Diabetes Is Seen Much before the Onset of Microvascular Complications
Lipopolysaccharide (LPS)/Endotoxin is hypothesized to play an important role in chronic inflammation associated with Type-1 diabetes (T1DM) and its complications. Endotoxin core antibodies (EndoCAb), LPS binding protein (LBP) and soluble CD14 (sCD14) act as modulators of LPS induced activation of innate immune system in vivo. Compared to normal glucose tolerance (NGT), T1DM subjects (both with and without microvascular complications (MVC)) had significantly higher levels of LPS, reduced levels of LBP and EndoCAb along with significant increase in the levels of IL-1β, IL-6, TNF-α and GM-CSF (p<0.05). No significant change was seen in the levels of these biomarkers between T1DM subjects with and without MVC.
Decreased levels of EndoCAb and LBP suggest sustained endotoxin activity in T1DM subjects even before the onset of microvascular complications.
Serum levels of LPS (a), LBP (b), sCD14 (c) and EndoCAb (d) were determined in NGT (n = 64), T1DM without MVC (n = 97) and T1DM subjects with MVC (n = 36) by immune-assays. Each dot represents individual values with the horizontal line representing the geo mean. 36 T1DM subjects without MVC and 26 with MVC had undetectable levels of EndoCAb.